Phase 2b Study of EVO756 in Adults With Atopic Dermatitis
Phase 2 – studying effectiveness and dosage
Conditions:
Atoptic Dermatitis
Sponsor: Evommune, Inc.
trial.available_in:
БГ
Overview
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
Who can participate
Inclusion Criteria:
* Chronic AD that has been present for ≥6 months
* Validated-Investigator's Global Assessment score of ≥3
* EASI of ≥16
* BSA of AD involvement of ≥10%
Exclusion Criteria:
* Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
* Use of certain medications
* Presence of skin comorbidities or other condition(s) that may interfere with study assessments
* Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry
БГ